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Pharmaceuticalisation and ethical review in South Asia: Issues of scope and authority for 
practitioners and policy makers. 
ABSTRACT 
 
Ethical review by expert committee continues to be the first line of defence when it comes to 
protecting human subjects recruited into clinical trials.  Drawing on a large scale study of biomedical 
experimentation across South Asia, and specifically on interviews with 24 ethical review committee 
[ERC] members across India, Sri Lanka and Nepal, this article identifies some of the tensions that 
emerge for ERC members as the capacity to conduct credible ethical review of clinical trials is 
developed across the region.  The article draws attention to fundamental issues of scope and 
authority in the operation of ethical review.   On the one hand, ERC members experience a powerful 
pull towards harmonisation and a strong alignment with international standards deemed necessary 
for the global pharmaceutical assemblage to consolidate and extend.   On the other hand, they must 
deal with what is in effect the double jeopardy of ethical review in developing world contexts.  ERC 
members must undertake review but are frequently made aware of their responsibility to protect 
interests that go beyond the ‘human subject’ and into the realms of development and national 
interest [for example, in relation to literacy and informed consent].  These dilemmas are indicative 
of broader questions about where ethical review sits in institutional terms and how it might develop 
to best ensure improved human subject protection given growth of industry-led research.   
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Pharmaceuticalisation and ethical review in South Asia: Issues of scope and authority for 
practitioners and policy makers 
From time to time, terms appear in the social sciences which help in capturing a biomedical zeitgeist.  
Notions such as ‘medicalization’ and ‘geneticisation’ (Lipmann, 1991; Hedgecoe, 1998; Have, 2001) 
have in the past provided a simple shorthand for the ways that social, economic and technological 
changes begin to reshape the landscape of health care and the experience of those that pass 
through it. In similar fashion, pharmaceuticalisation has entered social science discourse. Williams et 
al., (2011) provide a critical evaluation of this concept and its utility in understanding the pervasive 
impact of pharmaceuticals within medical systems, economies and societies [also see Abraham 
2011]. Consistent with their intention to give greater specificity to the pharmaceuticalisation thesis, 
we set out in this article to interrogate some of the ‘upstream (macro) level processes’ (2011: 712) 
that come within the ambit of pharmaceuticalisation.  The arena we consider is one which is 
increasingly important in understanding the growth and development of pharmaceuticals in society 
but one that is often lost in a bias towards Euro-American  accounts of this process.  Here we bring 
together globalisation, governance and the ethical review of clinical trials involving human subjects 
in the developing world.  The main sites we consider are research ethics committees and the 
responses of their members to a growing number of protocols for industry-sponsored clinical trials. 
What we show through this analysis is the way that the growing engagement with pharmaceutical 
interests across South Asia produces significant tensions for ERC members.  Beneath the 
documentary and procedural claims to standardised measurement, rules and disinterested 
evaluation in ethical review, industry-sponsored clinical trials generate concerns about scope, 
legitimacy and authority for those whose job it is to undertake and develop credible ethical review 
[cf Timmermans and Almeling, 2009;Timmermans and Epstein, 2010]. Whilst, such tensions are likely 
to be evident in any context where research ethics and economic interest coalesce, we argue that in 
developing world settings there are other factors in play that give these questions a particular 
urgency and complexity.  
Our stepping off point in considering the relationship between ethical review and clinical trials in 
South Asia is a question posed by Rachel Douglas-Jones in her doctoral thesis on capacity-building in 
ethical review in Asia:  ‘what are the problems to which the ethics committee is a solution?’ [2013, 
p34].  The question is an important one. Ethical review committees play a crucial role in the 
regulation of experimentation involving human beings.  In the most basic of terms, the approval of a 
formally constituted body of experts should ensure that research is beneficial, scientifically valid, 
and, above all, safe for those who participate. Yet, whereas in Europe and North America ERCs may 
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have reached a degree of institutional integration and stability, they are still very much in a state of 
development in parts of the world that have only recently been drawn into the rapidly growing 
demand for experimentation involving human subjects.  South Asia is a case in point. Capacity for 
ethical review is rapidly developing across the region and ERCs currently follow a broadly similar 
institutional and procedural format. Regional capacity-building has developed in association with 
organisations like the Forum for Ethical Review Committees in Asia and the Western Pacific 
(FERCAP), the Strategic Initiative for Developing Capacity in Ethical Review (SIDCER) and the Global 
Forum on Bioethics (GFB) all of which work to build capacity when it comes to the review of projects 
locally.  Affiliation to these organisations and the establishment of local branches [for example, 
FERC- Sri Lanka and FERC-India] is an important route to harmonisation and the dissemination of 
good practice.  Arguably however, the more powerful source of standardisation for review of 
industry conducted trials has been the ICH-GCP guidelines which aim to provide ‘a more economical 
use of human, animal and material resources, and the elimination of unnecessary delay in the global 
development and availability of new medicines whilst maintaining safeguards on quality, safety and 
efficacy, and regulatory obligations to protect public health’. (ICH, 2005).  Drawing on a genealogy of 
crisis reaching back to the Declaration of Helsinki, the ICH-GCP lays down detailed benchmarks for 
the ethical and scientific conduct of trials. Yet, linking the work of ERCs with a genealogy of universal 
human rights in this way provides significant cover for the extension of commercial pharmaceutical 
research (Abraham, 2007. Abraham and Reed, 2002).  In this view, ERCs are the handmaiden rather 
than the governor of trial activity with ethical review seen as essentially procedural, bureaucratic 
and rule observing.  Earlier studies suggest that in countries that have embraced standard guidelines 
and particularly the ICH-GCP guidelines, ERCs are apt to operate in ways that appear to be more 
about legal defence of researchers rather than actual protection of subjects [Bosk, 2007; Kleinman, 
1999; Stark, 2012].Our analysis confirms these concerns, and shows ethics committee members 
raising issues that are not limited to human subject protection per se but drawing in a range 
problems which afflict large numbers people in their society  [for example, poor access to resources, 
corruption, illiteracy,  inequality to name but a few]. These issues are articulated at a variety of 
scales [the person, the hospital, the University, the research community, the vulnerable, the nation 
state, the developing world and so forth].  Yet, the reality faced by many ERC members is one of 
growing pressure to accomplish human subject protection by narrowing the focus of ethical review 
such that it is clearly in line with industry specified guidelines. 
 
Methods.  
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The data on which this paper is based are drawn from a study of the growth of clinical trials and 
human experimentation in South Asia [India, Nepal and Sri Lanka]. 
I   
In this study we identified key 
actors in the conduct, management  and regulation of clinical trials in a variety of settings [See table 
One].  
TABLE ONE ABOUT HERE 
In total we carried out 337 semi-structured interviews, the vast majority of which were 
recorded, translated into English where necessary, and transcribed. The resulting dataset was 
entered into Atlas.ti for coding. The codes were generated by an iterative process at a workshop 
held in Mumbai with all coders present; trial codings were carried out and a selection of interviews 
was recoded to ensure consistency. 
Here we draw principally on extended interviews with a small sub-set of Ethical Review Committee 
[ERC] members from India [14], Sri Lanka [6] and Nepal [6].  In many respects,  the sample is 
unrepresentative of the wider body of reviewers at work in each of these countries as it was self-
selecting and therefore tended to be made up of people who were knowledgeable, articulate and  
keen to express their views on the rights and wrongs of  clinical trials, the work of ERCs and their less 
responsible colleagues.  They were also mostly from Institutional [hospital] and University settings. 
Nonetheless, consideration of their accounts of topics such as ethical review, operation and 
composition of committees, capacity building, training for reviewers and approaches to informed 
consent provides a useful indicator of the major challenges faced by committed ERC members in the 
settings identified.  We also draw to a lesser extent on interviews with regulators, policy-makers, 
academics and investigators involved in developing ethical review infra-structure.  Before 
considering these responses in detail it is necessary to consider briefly the three contexts in which 
our study took place. 
India  
India has a well-established pharma industry dating back to the 1950s.  The thrust of this industry 
has been the production of generics for local markets.  This infrastructure, combined with large 
numbers of English speaking doctors and technicians, as well as  large populations of treatment 
naive people with a range of disorders of interest in the west [eg cancers, cardio-vascular disease, 
diabetes]  has stimulated much interest in clinical trials.  Trials are outsourced by western 
pharmaceutical industries as well as conducted by local companies keen to move into global markets 
for their products.  Acceleration in this sector of activity has overwhelmed existing machinery for 
ethical review and monitoring which previously catered mostly for locally conducted research.    
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Along with Ethical Guidelines for Biomedical research Involving Human Subjects [Indian Council of 
Medical Research] 2000, the ICH-GCP guidelines have provided the framework for the conduct of 
ethical and scientific conduct of trials.  In 2001, ICH-GCP India were created (CDSCO, 2001), adapting 
the generic guidelines to fit local circumstances.  In 2005, the ‘Schedule Y’ amendment of the Drugs 
and Cosmetic Act provided further guidance on the constitution and responsibilities of ethics 
committees.  To date, ERCs have largely operated within the institutions in which the trials have 
taken place.  The ICMR has launched various initiatives to encourage the take up of standard 
operating procedures against a backdrop of poor regulation and variable quality of the review 
process.  The Forum for Ethical Review Committees – India [FERCI] was established under the 
auspices of FERCAP to improve quality and standards and held its first conference in 2011.   In 2007, 
the ICMR established its own clinical trials registry.
ii 
   At the time of writing, there over 650 ERCs 
registered via the Clinical Trials Registry of India.
iii
  The workload of ERCs is unevenly spread with a 
relatively small number of ERCs dealing with the majority of trials and a disproportionate number 
using independent ERCs.   
 
Sri Lanka 
Sri Lanka has neither the population nor the pharmaceutical industry that India has.  Not surprisingly 
therefore, the development of ERCs looks very different.  All the major medical faculties and 
teaching hospitals currently have their own institutional ethical review committees, making for some 
15 committees (Dissanayake, Lanerolle and Mendis,  2006).  The Sri Lanka Medical Association 
(SLMA) formed its ethics committee in 1991 and began considering research projects carried out by 
its members in 1999.   In 2005, the Forum for Ethical Review Committees in Sri Lanka [FERCSL] was 
established along with Uniform Guidelines for ethical review  (Dissanayake, Lanerolle and Mendis,  
2006).  However, take-up of the guidelines appears patchy with considerable variation in standard 
operating procedures in evidence. The increase in the number of ERCs and the quality of their 
capacity to review projects was in part driven by an increase in international collaborative research 
being conducted in Sri Lanka as well as by the desire to create robust research governance of the 
kind needed to attract trials in the future. Sri Lanka has also recently created its own clinical trials 
registry.
iv
  As in India, ERCs are a key mechanism in the regulation of trial activity but they are also 
identified as having serious weaknesses that need to be addressed  if they are to be effective 
(Karunananyake, 2012). 
 
Nepal  
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Nepal is by far the smallest player in the emergence of human experimental activity in Asia and 
consequently has a very recent and modest history of ethical review. The central body regulating 
research studies in Nepal is the apex Ethical Review Board (ERB) of Nepal Health Research Council. 
The 20 Institutional Review Committees (IRCs) that operate mostly in the medical schools have been 
approved by the national ERB. The IRCs came in existence because of increasing volume of local 
research studies seeking approval from ERB. IRCs are not currently authorised to review 
international trials which must be reviewed at ERB level. National Ethical Guidelines for Health 
Research in Nepal were published in 2001.  A National Guideline on Clinical Trials with the use of 
Pharmaceutical Products was published in 2005. Phase I and Phase II trials are not currently allowed 
and as a consequence Nepal has not been a target for growth in these activities with the increase in 
research mostly being carried out by international charities, NGOs and academic bodies [Khatri, Raj 
Jeevan and Harper,nd]. 
 
The rise of human experimentation in Asia. 
The earlier attitude was that we should block it [clinical trials development]  because as I told 
you it was a nation of traders at that time and now because our own people are innovating, 
we want the innovation to be there, we want to be landscaped for the innovation, so the 
trials are to be permitted but then at the same time the ethical standards have moved up, 
benchmarks have increased, every trial has to be put on the web and everything has to be on 
the web, so it is an open system, so in that you don’t feel threatened; not at all but the only 
thing, I feel heavy as a person. Senior Government of India Official [022] 
 
…[ the government].. want to promote clinical trials more as a money making exercise than 
anything else I guess, because clinical trials are big money, and we have a good receptive 
population here, educated and also the free health care which means that people need not 
bother about funding health care for the patients with side effects or anything, that 
automatically falls on the state to fund all that, so it’s a very practical place for clinical trials. 
Sri Lanka ERC member [71] 
 
Before 1990, there are people who brought medicines in bags and distributed but after the 
formation of Nepal Health Research Council in 1991, every health research in the country 
should take ethical approval from them. I am ‘dead against clinical trials’. My soul just 
doesn’t agree to it. There are vulnerable groups like poor people, army, students, 
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handicapped people who are being tested. We should not encourage it [clinical trials]. ..[].. . 
Newer biological products should not be tested in humans. There are also DDA regulations to 
be cleared in Nepal.  NepalERC member [03] 
 
In the three quotations given above, something of the ambivalence that those with responsibility for 
ethical review feel about clinical trials sponsored by commercial trials organisations is evident.  On 
the face of it, the economics of experimentation are undoubtedly attractive.  Saving costs on drug 
development, opening up new markets and even developing entirely new drugs using local expertise 
has the potential to reconfigure the shape of the pharmaceutical industry across the globe.  In 
anticipation of such developments, extravagant claims have been made for the contribution that 
clinical trials will, in due course, make to economies in the region and particularly in India.  These 
claims have stimulated the promotion of trials, training of personnel and capacity building in the 
knowledge and expertise needed to conduct trials in accordance with international standards.  Much 
of this activity is intended to create a climate in which home-grown as well as outsourced clinical 
trials will thrive; the promise is nothing short of a pharmaceutical El Dorado.   
 
On the way to this El Dorado, however, serious concerns have been raised.  Many of these concerns 
are by now familiar and well-rehearsed; they draw attention to the potential for abuse and 
exploitation of ‘human subjects’ in trials.  This may range from the inadequacy of informed consent 
procedures through to physical harm and even death as a result of adverse drug reactions for which 
there may then be little or no compensation, giving rise to charges that local populations are used as 
‘guinea pigs’ with ‘double standards’ in operation[Macklin,2004].  There are concerns that groups 
rendered vulnerable by their marginality, poverty and lack of literacy are being caught up in the 
‘global search for human subjects’ [Petryna, 2009].  In the ensuing debates, ERCs figure as both a key 
mechanism in enabling trials as well as a site of potential activism aimed at drawing attention to 
abuses and the broader issues of inequality that often underpin these. ERC members frequently 
indicated their awareness of vulnerable research subjects and their duties and responsibilities in 
ensuring their protection: 
 
….  the people who are in the ethics committee, they really see to it that the patient’s rights 
are properly taken care of … because they don’t know anything scientifically   India, ERC 
member [003] 
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The problems identified, however, were not just downward facing ones.  ERC members in each 
country spoke of their responsibilities to feed issues and concerns up into legal and policy-making 
machinery.  Here, the concerns were much more about ‘national’ interest and how it might be 
sidelined, undermined or over-ridden in the quest for viable experimental economies.  One 
informant spoke of ‘research coolies’, an emotive term intended to invoke parallels with other arena 
in which domination and exploitation of developing world populations is underway.  This was 
particularly so in India following a change of law in 2005 which allowed easier access to 
pharmaceutical companies to local populations  [see Nundy and Gulhati, 2005].  Similar, sentiments 
were evident in Sri Lanka:  
 
...   the problem is we need to upgrade our societal knowledge levels, preparedness must be 
upgraded, if that [successful engagement with international clinical trials] is to actually work 
in that way, otherwise it won’t, it will be a new kind of colonialism. That’s the problem. Sri 
Lanka ERC member  [074] 
 
 
In response to these problems, members of ERCs spoke optimistically of a progressively stronger, 
more confident and better organised infrastructure out of which robust and consistent responses 
could be applied to international and locally sponsored research proposals 
 
……  we have a strong procedure right now. Earlier there was hardly any procedures and now 
we have an application form, even including a standard operating procedure is available for 
the investigators to check..[].. one of the biggest advantages came for the ethics review 
parties the ICMR guidelines which came in 2004, ‘05 which actually helped a lot to formulate 
how an ethics committee should function in the country.   India ERC member [009] 
 
…  ethics committees have evolved. The type of questions that we use to ask and the issues 
we used to raise 10 years ago are different from what we raise now. And by and large the 
bar has risen. And therefore even investigators have refused trials, I know. And in fact many 
of them involve me in that pre-nup discussion. You know, before they firm up with the 
company they will, they have ethical issues they want to know from me also whether these 
are ethical issues, whether these will cause problems. So they do want to iron it out. …[].. the 
investigator community needs to be convinced that the ethics committee is a policeman, but 
a strict policeman,  but not somebody who is against us. But [someone] who wants to 
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promote good ethical research. And has ultimately got the patient’s good at heart.  India ERC 
member [002] 
 
Yet, despite these claims to progress, there was a sense in which the work of committee members 
was a small response in the face of a much bigger problem.  Most of the ERC members interviewed 
were voluntary.  Their work involved long hours and exacting work dealing with an unfeasible 
workload with the threat of possible hostility from researchers in the background should they give 
unfavourable decisions.  Nonetheless, many of those interviewed expressed strong commitment and 
dedication to their work.  Indeed, some spoke with enthusiasm bordering on evangelical zeal about 
the importance of ethical review and the need to extend its scope and improve its thoroughness.  
 
However, the management of ethical review in practice was likely to be rather more pragmatic and 
tactical. As a comment from a member of an ethics committee in India makes clear, social and 
humanitarian concerns are less in evidence as other priorities take over 
 
….   according to me if a person is recruited as a subject of research and it is deemed by a 
component ethical review board and set of researchers, that there is no ethical wrong or 
scientific wrong in that person being recruited I don’t see why Indian subjects can’t be 
recruited for clinical trials. So, yes, ok Indian patients are being made guinea pigs for 
molecules. If it is being done in the right way I don’t see anything wrong. ..[].. I suppose there 
are many agencies which are conducting clinical trials which are not earlier into ethical 
standards or scientific standards that is required. I don’t know about that. But as far as we 
are concerned I don’t see any thing wrong. India ERC member  [001] 
 
In this rather straight up and down reading of ethical review, the scope and function of ERCs is 
simple and clearly limited to the research protocol and the assurances given therein.  The attraction 
of this approach, particularly among younger researchers, appeared to be that it offers both 
procedural efficiency and authoritative outcomes in circumstances where complexity and the sheer 
volume of work might otherwise overwhelm.  In the midst of this tension, our research identified a 
powerful and emerging alignment.  In managing the growing volume of protocols to review, ERCs 
appeared to be cleaving to ICH-GCP as a route to procedural clarity.  At the same time, they also 
found themselves in competition with a new breed of ‘independent’ and, indeed, internationally 
sponsored ERCs.   
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These organisations were beginning to feature in the ethical review landscape of India and to a 
lesser extent in Sri Lanka.  Constituted and practicing in conformity with ICH-GCP from their 
inception, they offer a commercial route to ethical approval.  Their emergence causes concern to 
those who have laboured to develop capacity and rigour in the work of institutional review bodies.  
Concerns expressed were twofold. First, the guidelines followed can be interpreted quite minimally 
and specifically and whilst scientific rigour is likely to be guaranteed [because otherwise the validity 
of the data would be compromised] issues of patient safety are likely to be treated in a more 
procedural fashion.  
 
Furthermore, a route to ethical approval which circumvents a more politicised reading of ethics and 
what it means to protect a ‘subject’ is highly attractive to those wishing for a speedy review.  This 
tension is most evident in industry sponsored clinical trials which are likely to be multi-centred.  
Here industry standards enshrined in the ICH GCP create expectations of high levels of conformity 
between trials.  ERCs have less of a role to play in such trials, primarily because the protocols are less 
negotiable but also because large pharma companies, particularly foreign ones, have both the 
resources and the experience to draft scientifically sound and ethically plausible protocols.   As one 
PI on a commercial trial in India put it: ‘Sponsors are very clear. They want safety data, efficacy in the 
Indian population. That’s all. Nothing more’  India Clinical Trial PI [004].  In the drive towards 
procedural efficiency and auditable outcomes, trialists, both commercial and non-commercial,  end 
up paying less attention to the wider socio-economic contexts in which trials take place.  Complex 
questions of just what is informed consent and how to get it, and what  the benefits are for those 
who participate in research are apt to be occluded in the face of pharma induced proceduralism.  
This is not to say that these issues are absent from protocols but rather that, in the complex chains 
of responsibility and accountability that lie between a professionally crafted and ethically approved 
application and its implementation on the ground, there is much scope for the interests of trial 
participants to become secondary to the conduct of the trial and the data it sets out to generate.  
This problem is further compounded by the fact that it is often junior staff with minimal training who 
are responsible for the implementation of agreed protocols at the level of day to day interaction 
with research participants. 
 
 
The emergence  of independent ethics committees within the ERC landscape adds further 
momentum to this process, with concerns being expressed about their independence [Karam and 
Karandikar, 2012; also see Emmanual,Lemmens and Eliot, 2006].  For many of those interviewed,  
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ethical review was not a legitimate area for commercial activity because of the tension it creates 
between robustness of review procedures on the one hand and the likelihood of future use of 
particular ERCs by CROs and their sponsors on the other:  
 
..  If an independent ethics committee is very cautious, and they fear that if they don’t 
approve, it [the trial] easily goes elsewhere and they get the approval from there. Like EC 
shopping. There is nothing to prevent that.  India  ERC member [002]. 
 
The minute they realize that there is something going wrong, when we ask uncomfortable 
questions, they just go to some other committee  India ERC member [001] 
At the time of writing [Jan 2014] the Drug Controller General of India has forbidden independent 
ethics committees from approving clinical trial protocols following complaints about procedural 
irregularities.
v
  Further steps have been taken by the Supreme Court of India to establish more 
stringent monitoring of trials including registration and accreditation of ERCs which will, in future, 
also have increased responsibilities for monitoring and reporting.
vi    
Neither Sri Lanka nor Nepal has 
the kind of demand that would currently make independent ethics committees viable.  Nonetheless, 
as we will see in the next section the issues of legitimacy and jurisdiction that their existence raises is 
much wider than India alone. 
 
ERCs and the question of legitimacy and authority. 
ERCs feature in a complex landscape of interests and concerns.  These are at once economic and 
humanitarian; legal and social; national and international.  Procedural legitimacy and authority is 
drawn from their location within particular institutions.  These include Universities, Professional 
Associations, Hospitals and government departments and institutes with committees assembled out 
of suitably representative experts.  ERCs also derive their authority from a patchwork of guidelines 
and regulations that emanate from different sources: government, industry, academia and 
international NGOs.  Reference to these sources enables ERCs to gain credibility and acceptance 
among local and international researchers.  They provide members with an ethical charter of sorts 
which validates and legitimates action. 
 
We are SIDCER approved, and basically …[]…, there is the FERCSL national guidelines on 
writing your standard operating procedures and doing the ethics review and we basically 
follow that to the letter, so our is already readily available you can find it or I can give you a 
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copy, everything is in writing and it’s very easy to understand, it’s all tick boxes and check 
lists and we are very transparent in the whole review, so really that’s what we follow and at 
the moment we are reviewing our SOPs also, and probably that’s of course just our 
procedures I think you may have to also look at our criteria for review and see whether we 
can improve on that. It is very standard everybody does the same thing within our EC.  Sri 
Lanka ERC member [071]. 
…  we have developed our SOP’s based on ICMR, ICH and FERCAP guidelines, so we follow 
those. And now because we have an SOP we are stronger in saying certain things – India ERC 
member [156]. 
 
Unlike in Sri Lanka and Nepal, there is an expectation in India that the responsibilities that figure in a 
research application will be legally recognised and approved: 
 
Interviewer: In India CRO PI, investigator and director all sign an agreement relating to the 
collaboration? 
Respondent: Yes. That is reviewed. But it comes to the ethics committee; it also goes to our 
legal expert. You have a (hospital ethics committee) legal expert. He also clarifies that, gets 
things done the way the hospital is supposed to have it legally and it also comes to the ethics 
committee to have a final look at that. This goes simultaneously; when they put in support 
for the scientific review they will immediately send the CTA to the legal expert office. India 
ERC member [156].   
 
Whilst these forms of regulatory triangulation increase confidence, they also raise concerns about 
over-excessive and disabling regulation among researchers.  ERCs as mechanisms that enable and 
facilitate better research, give way to rather more antagonistic readings of the role of ERCs among 
researchers with concerns expressed that ERCs address problems that are not within their sphere of 
responsibility: 
 
I mean we are talking about ethics; we are talking about bad science which is impeaching on 
ethics. They do ask, ‘who are you, what is this? This is (name of the respondent)’s EC please, 
we should try to avoid it’. So we have people like that. So it’s not that simple. … whoever has 
to work as regulators are never popular people, by definition.   India ERC member [002] 
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However, in contexts where authority is weak and mistrust is high, invoking rhetorics of legitimacy, 
such as audit, monitoring, surveying and certification by higher authorities, is one of the few 
strategies available to persuade outsiders of the committee’s authority to make legitimate 
pronouncements on the ethics of research.  Such credentials are essential when it comes to an ERCs 
ability to act as what Stark has referred to as a ’declarative body’, that is, one capable of making 
judgements and evaluations but, most critically, decisions which will be accepted as emerging from a 
democratic process [Stark, 2012,  pp4-5].  
 
The power of ERCs is, therefore, largely negotiated rather than absolute, based on guidelines rather 
than laws and persuasion rather than instruction.  Whilst great strides have been made in 
channelling more research through ERCs and cultivating the confidence of researchers, there remain 
anxieties about the limits of their power and a sense that all their good work might be undone once 
the project passes beyond the ERC and into its implementation phase.   For example, in Nepal and  
Sri Lanka, once a project is approved it is very much a matter of trust and investigators’ willingness 
to self-report on how the trial is implemented.  For one of our informants, this issue was further 
linked with lack of capacity within the committee: 
 
…  there’s no training, we don’t have people who have trained in it [ethical review], it needs 
training, monitoring, for the moment we have done the consent monitoring and then we 
have depended on adverse events from the investigators,  ..[]... We do not have the staffing 
or the training. Sri Lanka ERC member [076] 
For this ERC member, establishing a functioning ERC, simply served to highlight the partiality of the 
process; there was an awareness that many further steps would need to be taken to ensure that 
monitoring was both comprehensive and rigorous.  The committee simply made apparent the 
magnitude of the problem of policing projects once approved. 
Problems of ERC scope, however, are not just about jurisdiction.  Other concerns arise for ERC 
members when they consider the limits of their roles and responsibilities towards subjects who they 
will never know.  The moral complexity of the issues that they are expected to deal with are 
substantial. As one of our Indian informants candidly put it:  
….  I find it very difficult to put myself in the feet of the completely uneducated women from 
Uttar Pradesh.  I find it impossible to do so. Which means to know how she would think and 
how she would react to a situation is impossible for me? Which means then we need them 
[ERC members] to discuss this, to come up with a guidance document. Like I told you, to talk 
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to this cancer survivor, completely different thought process came in to my mind, that you 
have to think of it from too many different sources.  India ERC member [002]. 
What this quotation points to, is a profoundly humanistic conception of the role of ERCs but one that 
is often lost to procedure and pragmatism.  The starting point for any application is a research 
protocol. The style of the protocol is invariably technical and constructed in such a way that 
researchers and ‘subjects’ are described impersonally and with maximum detachment – socially and 
culturally these documents are flat, and intentionally so.  It is the skill of the person drafting the 
research protocol, and particularly in pharmaceutically sponsored multi-centred trials, to produce 
such documents. However, through ethical review, there is some presumption that the social 
imagination of the reviewers will be brought into play.  It is, in theory at least, the task of the ethics 
committee to animate the protocol, that is, to try to imagine the people who are likely to end up in 
the trial and the worlds in which they live.  Arguably, this is why social scientists and lay people are 
brought on to ERCs and why there is currently a great deal of interest in community advisory boards 
as ways of amplifying the voice of those who end up in trials [Weijer and Emmanuel, 2000].  The 
purpose of such a mechanism is precisely to help stimulate acts of imagination and empathy capable 
of invoking the people and relationships with which the protocol will ultimately engage.   
…  you can’t define risk only as physical risk. People just forget social risks, economic risks 
and psychological risks.  India ERC member [002]. 
However, putting oneself in another’s shoes in the context of a busy ERC is both challenging, time 
consuming and deemed by some to be wholly misplaced.  Consequently, there is a danger that the 
human subject that features at the heart of an ERC’s deliberations will not be any actual person in a 
real place and time but the trans-cultural, trans-historical, universal subject which features in all 
protocols.  At this juncture, ICH-GCP offers an attractive route to consistency in the conduct of 
clinical trials and particularly its focus on the informed consent transaction as the primary index of 
ethical conduct.  However, the economic and cultural questions that exercise some ERC members 
are apt to be obscured or overlooked. 
In India in particular, limitations in terms of resources, training and the absence of clearly defined 
statutory duties render the limits of ERC responsibilities fuzzy at the margins.  Indeed, the scale and 
complexity of activity means that the possibilities for breaches of regulation are rife. A current 
concern of a number of informants was the potential for moving activity to the edges of regulatory 
reach whether this be in terms of the regions in which trials are conducted or the committees 
through which trials are put.  As a result there have been calls for ERCs to have ‘teeth’ and a clearer 
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articulation with law and state regulation.   Proposals to amend the Drugs and Cosmetics Act [1940], 
as mentioned above, have specified that ethical approval for clinical trials can only be given by ERCs 
that have been registered with the licensing authority.   This development further ties in the practice 
of clinical trials with the ICH-GCP India Guidelines via the formal registration of ERCs.  The 
amendment also gives the Central Drugs Standard Control Organisation the power to inspect the 
documentation of an ERC at any time. 
 
Conclusion 
We began our considerations of ERC members’ views with a question:  if ethics committees are the 
solution what is the problem?   In reflecting on the impacts of industry sanctioned models and 
strategies for ethical review in the developing world it would seem that there are a range of 
problems, some of which extend the business of human subject protection beyond the immediate 
engagement between a trial participant and a treatment being tested in an RCT.   In this article we 
have provided insights from those who are, in many respects, at the eye of the storm when it comes 
to the governance of clinical trial activity.  On the one hand, ERC members articulate a need for 
contextualisation and localisation in the attempt to render trials ethical in developing world settings 
(cf Emanuel et al 2004, Lavery, et al., 2007).  Here, ERC members we interviewed, allude to issues 
that confound their efforts to protect subjects, such as poverty, literacy and structural inequality.  
Achieving a satisfactory ethical review might, in other words, inspire advocacy and social critique.   
On the other hand, however, they face considerable pressure.  Their work load is substantial, they 
are under-resourced and there is a strong push to standardise and regularise the work of ethical 
review in ways that remove the independence of reviewers to set the scope of their concerns. 
These tensions are not just national or indeed regional phenomena but are fuelled by changes that 
are taking place in Europe and US which are aimed at increasing research capacity and velocity by 
means of an alignment between ethical review and industry standards and procedures. For example, 
at the time of writing, the EU is proposing to replace the existing clinical trials directive with a new 
regulation aimed at accelerating application procedures and harmonising administrative 
requirements for multi-centre trials across the European Union and in countries participating in trials 
beyond the EU (Den Boer and  Schipper,  2013).  In the US, Food and Drugs Administration (FDA) 
proposed that the International Conference on Harmonisation - Good Clinical Practice (ICH-GCP) be 
designated as the new regulatory standard which in effect sidelined the Declaration of Helsinki for 
trials carried out outside the US. (Goodyear et al., 2009).  Both of these developments have 
significant implications for the role that ethical review might play in attempts to safeguard trial 
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participants from harm and exploitation.  Given that ethics committees may not be able to provide 
the kinds of protection that vulnerable people need we ought to ask  a further question:  if ethic 
committees are the problem, what is the solution?   
That ethics committee are currently a problem in the countries considered might be inferred from 
the ways in which clinical trials activity has generated debate, stimulated activism and stirred those 
responsible for the governance of research to put forward improved regulatory responses.   For 
example, since our data was collected, responses to public concerns over clinical trial regulation in 
India have resulted in a wide range of new regulations coming from the Supreme Court, the Office of 
Drugs Controller General of India and a series of expert panels. Registration of ethics committees, 
audio-video recoding of the informed consent procedures and clearer rules regarding compensation 
for deaths and injuries that occur during clinical trials are all now mandatory.
vi
  In Sri Lanka, the 
drafting of a new Clinical Trials Act has provoked controversy as it is believed by some to lower the 
regulatory threshold thereby making it easier to conduct clinical trials (Siribaddana and  Bandara, 
2013).  In Nepal, whilst debates about  commercial trials have only just begun, there is much  
interest in regulating research activities and promoting ethical standards in the conduct of both 
clinical and public health research.  Significantly, in each of these places,  ERCs are identified as the 
problem but they are also identified as the solution when it comes to better research governance. 
Yet, when it comes to what constitutes effective and legitimate ethical review, the language of ICH-
GCP is a strong card to play.  One of the reasons for this is the ease with which techniques of 
verification such as monitoring, audit, record keeping, documenting and other evidence making 
procedures familiar to scientists, can be imported into the practice of ethical review.  However, the 
failure of ethical review to protect human subjects beyond the informed consent transaction does 
not result in a change of method but typically better monitored replications of the same process.  [cf 
McGoey, 2010].   One consequence of this move in the US has been a tendency to replicate the 
evidential turn in science through an evidence-based ethics in that it would similarly, '….  emphasize 
the importance of data in informing decision and decision-making about the ethical issues inherent 
in clinical medicine and research' [Sugarman, 2004, p495]. The tendency to instrumentalise ethics in 
this way was evident in the accounts of a number of researchers interviewed. Rather than seeing the 
directives of an ERC as the beginning of an ongoing awareness of the wide-ranging vulnerability of 
their subjects, many researchers spoke of ethics as a kind of object; something obtained from, or 
‘given’ by, the ERC which then enabled them to continue with a clear conscience.   
Notes. 
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i
   The research was funded by the UK’s ESRC/DfID [nbrRES-167-25-0503].   Ethical approval for the 
study was initially given by the School of Social and Political Sciences Research Ethics Committee, 
University of Edinburgh [13/10/2010].   Ethical clearance was then gained from local ERCs for 
research to be carried out in India, Nepal and Sri Lanka. 
ii 
The Clinical Trials Registry India. http://www.who.int/ictrp/network/ctri/en/index.html accessed 
23rd July 2013. 
iii.  Details of registered ERCs can be found on the website of the Central Drugs Standard Control 
Organisation:  http://www.cdsco.nic.in/forms/Default.aspx accessed 5th Feb 2014 
iv   The Sri Lanka Clinical Trials Registry (SLCTR) is a Registry for clinical trials involving human 
subjects, conducted in Sri Lanka or overseas. The SLCTR is a Primary Registry linked to the Registry 
Network of the International Clinical Trials Registry Platform of the WHO (WHO-ICTRP). It is a not-
for-profit Registry, with free and open access to researchers, clinicians, and the general 
public’.http://www.slctr.lk/ accessed 21
st
 July 2013. 
v.  http://pharmabiz.com/ArticleDetails.aspx?aid=76984&sid=1  accessed 13
th
 August 2013. 
vi.  Government set to tighten clinical trial norms.  Times of India 3/01/2014.   
http://articles.timesofindia.indiatimes.com/2014-01-03/india/45834762_1_clinical-trials-accreditation-
council-ethics.  Accessed 10
th
 Jan 2014. 
vii Panel recommends sweeping changes in clinical trials, The Hindu sept 18, 2013. 
http://www.thehindu.com/sci-tech/health/panel-recommends-sweeping-changes-in-clinical-
trials/article5141590.ece accessed 20th Jan 2014.  Also see Jesani 2102 & 2013 
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Category Nepal India Sri Lanka US, UK Total 
PIs and Co-Is 10 31 11 3 55 
Clinical Research Assistants 14 18 11 0 43 
Other trial staff 24 22 39 0 85 
Collaborators 0 3 1 1 5 
Sponsors and CRO staff 0 35 1 13 49 
Ethics committee members 6 14 6 0 26 
Regulators 2 7 2 6 17 
Other Key Informants 17 18 9 13 57 
Total 73 148 80 36 337 
 
Table One.  The BHESA interview data-set. 
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Pharmaceuticalisation and ethical review in South Asia: Issues of scope and authority for 
practitioners and policy makers 
 Research Highlights 
 
• In the review of trial protocols, tensions surround the scope, functioning and 
authority of ERCs 
•  ERC members expressed specific concerns  about responsibilities towards 
vulnerable populations 
• ERC members face pressure from the constituencies they serve. 
• ICH-GCP and evidence-based approaches to ethics narrows  the parameters for ERC 
concerns,  
• these developments suggest a novel impact of pharmaceuticalisation in the 
developing world. 
 
